Filing Details
- Accession Number:
- 0001787306-23-000066
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-06-02 20:31:18
- Reporting Period:
- 2023-05-27
- Accepted Time:
- 2023-06-02 20:31:18
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1787306 | Arcutis Biotherapeutics Inc. | ARQT | Pharmaceutical Preparations (2834) | 812974255 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1798679 | Masaru Matsuda | C/O Arcutis Biotherapeutics, Inc. 3027 Townsgate Road, Suite 300 Westlake Village CA 91361 | See Remark | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-05-27 | 4,875 | $0.00 | 43,976 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2023-05-31 | 1,830 | $7.80 | 42,146 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-05-31 | 1,463 | $6.38 | 43,609 | No | 4 | A | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct | |
| No | 4 | A | Direct |
Footnotes
- Represents Performance Stock Units ("PSUs") initially granted on January 3, 2022, that were subject to a performance-based vesting condition. The vesting condition was determined to be satisfied on May 27, 2022. The PSUs will vest fully on May 27, 2025, subject to the Reporting Person's continued service to the Issuer on such vesting date.
- Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the PSUs, the shares were sold upon the vesting of the PSUs solely to cover applicable withholding taxes.
- The transaction was executed in multiple trades in prices ranging from $7.79 to $7.86, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- Shares acquired pursuant to the Issuer's Employee Stock Purchase Plan.
Billionaire Hedge Funds
